GlassScriptPhysician profile
Adam J Goldrich
NPI 1912292517
$1,161.15
in general payments reported to CMS, 2019-2025
24 companies · $517 in 2025
The $517 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227 · 2020: $54.65 · 2021: $11.92 · 2022: $15.71 · 2023: $46.35 · 2024: $289 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $799 · Education: $53.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $798.76 |
| Education | $53.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $255.59 | 2019-2025 | |
| Abbvie INC. | $114.79 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $100.12 | 2019-2025 | |
| Celgene Corporation | $88.85 | 2024-2025 | Reblozyl |
| Genentech, INC. | $53.45 | 2025 | |
| Glaxosmithkline, LLC. | $49.28 | 2020-2025 | Zejula, Jemperli |
| Amgen INC. | $46.35 | 2023 | Blincyto, Kyprolis |
| Servier Pharmaceuticals LLC | $38.34 | 2024 | |
| Iovance Biotherapeutics, INC. | $37.05 | 2025 | Amtagvi |
| Lilly USA, LLC | $36.75 | 2019 | |
| Janssen Biotech, INC. | $35.19 | 2019 | |
| Invivyd INC | $35.07 | 2024 | Pemgarda |
| Azurity Pharmaceuticals, INC. | $31.88 | 2025 | Danziten |
| E.R. Squibb & Sons, L.L.C. | $30.77 | 2019-2022 | |
| Astellas Pharma US INC | $30.31 | 2025 | Padcev |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $25.62 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.38 | 2019 | |
| Telix Pharmaceuticals | $22.50 | 2025 | |
| Bioprotect Medical, INC. | $21.13 | 2025 | Bioprotect Balloon Implant System |
| Puma Biotechnology, INC. | $21.10 | 2025 | |
| Boston Scientific Corporation | $19.04 | 2024 | |
| Eisai INC. | $17.13 | 2020 | |
| Seagen INC. | $14.81 | 2019 | |
| Merck Sharp & Dohme LLC | $12.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Goldrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.